Page - (000347) - in Biomedical Chemistry: Current Trends and Developments

Reviews. Drug Discovery, 3(8), 711-715. Lal, J., Mehrotra, N., & Gupta, R. C. (2003). Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method—a pilot study. Journal of Pharmaceutical and Biomedical Analysis, 32(1), 141-150. Lanteri, C. A., Chaorattanakawee, S., Lon, C., Saunders, D. L., Rutvisuttinunt, W., Yingyuen, K., (2014). Ex vivo activity of endoperoxide antimalarials, including artemisone and arterolane, against multidrug-resistant plasmodium falciparum isolates from cambodia. Antimicrobial Agents and Chemotherapy, 58(10), 5831-5840. Le Garlantezec, P., Richard, C., Broto, H., & Rapp, C. (2014). Treatment of imported plasmodium falciparum malaria: Role of the combination of dihydroartemisinin and piperaquine. [Traitement du paludisme d’importation a Plasmodium falciparum : place de l’association dihydroartemisinine-piperaquine] Medecine Et Sante Tropicales, Marcsisin, S. R., Jin, X., Bettger, T., McCulley, N., Sousa, J. C., Shanks, G. D., (2013). CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: A possible metabolic link to blackwater fever. Malaria Journal, 12, 214-2875-12-214. Marcsisin, S. R., Sousa, J. C., Reichard, G. A., Caridha, D., Zeng, Q., Roncal, N., (2014). Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: Implications for the 8-aminoquinoline class of anti-malarial compounds. Malaria Journal, 13, 2-2875-13-2. Mehrotra, N., Lal, J., Puri, S. K., Madhusudanan, K. P., & Gupta, R. C. (2007). In vitro and in vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey—highlighting species similarities and differences. Biopharmaceutics & Drug Disposition, 28(5), 209-227. Milner, E., McCalmont, W., Bhonsle, J., Caridha, D., Cobar, J., Gardner, S., (2010). Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols. Malaria Journal, 9, 51-2875-9-51. Milner, E., Sousa, J., Pybus, B., Melendez, V., Gardner, S., Grauer, K., (2011). Characterization of in vivo metabolites of WR319691, a novel compound with activity against plasmodium falciparum. European Journal of Drug Metabolism and Pharmacokinetics, 36(3), 151-158. Mohammed, T., Erko, B., & Giday, M. (2014). Evaluation of antimalarial activity of leaves of acokanthera schimperi and croton macrostachyus against plasmodium berghei in swiss albino mice. BMC Complementary and Alternative Medicine, 14, 314-6882-14-314. Nevin, R. L. (2014). Idiosyncratic quinoline central nervous system toxicity: Historical insights into the chronic neurological sequelae of mefloquine. International Journal for Parasitology. Drugs and Drug Resistance, 4(2), 118-125. Noedl, H., Krudsood, S., Chalermratana, K., Silachamroon, U., Leowattana, W., Tangpukdee, N., (2006). Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated plasmodium falciparum malaria in adults: A randomized, phase 2 clinical trial in thailand. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 43(10), 1264-1271. Oliveira, R., Guedes, R. C., Meireles, P., Albuquerque, I. S., Goncalves, L. M., Pires, E., (2014). Tetraoxane-pyrimidine nitrile hybrids as dual stage antimalarials. Journal of Medicinal Chemistry, 57(11), 4916-4923. Opsenica, I., Burnett, J. C., Gussio, R., Opsenica, D., Todorovic, N., Lanteri, C. A., (2011). A chemotype that inhibits three unrelated pathogenic targets: The botulinum neurotoxin